ReviewJournal of cardiovascular translational research2013
Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.
Review in Journal of cardiovascular translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.Circulation. Heart failure · 2016Trial
- Calcium dysregulation in diabetic cardiomyopathy & heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2026Review
- Left ventricle function and post-transcriptional events with exercise training in pigs.PloS one · 2024Article
- Prognostic Role of Metabolic Exercise Testing in Heart Failure.Journal of clinical medicine · 2023Review
- Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction.Biomolecules · 2022Review
- The role of mechanotransduction in heart failure pathobiology-a concise review.Heart failure reviews · 2021Review
- Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction.Frontiers in cardiovascular medicine · 2021Review
- Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction.World journal of cardiology · 2020Review
- Anabolic Hormones Deficiencies in Heart Failure With Preserved Ejection Fraction: Prevalence and Impact on Antioxidants Levels and Myocardial Dysfunction.Frontiers in endocrinology · 2020Article
- Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.PloS one · 2020Observational
- Effect of dietary fat and sucrose consumption on cardiac fibrosis in mice and rhesus monkeys.JCI insight · 2019Article
- Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials.Annual review of pharmacology and toxicology · 2019Review
- Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes.Matrix biology : journal of the International Society for Matrix Biology · 2019Review
- Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients.Journal of clinical medicine · 2018Article
- Not all fiber is good for you: targeting fibroblast activation to improve cardiac function in heart failure.American journal of physiology. Heart and circulatory physiology · 2018Article
- Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.Archives of medical science : AMS · 2018Article
- Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi-Ethnic Study of Atherosclerosis).Journal of the American Heart Association · 2018Article
- Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction.Journal of cardiovascular translational research · 2017Article
- Article
- Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.BMC cardiovascular disorders · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprehensive diagnostic criteria, accurate prognostic indicators, and effective treatment for patients with heart failure and a preserved ejection fraction (HFpEF) represent a critically important unmet need in cardiovascular medicine. Novel approaches to fill this unmet need are likely to be facilitated by targeting the underlying and unique pathophysiologic mechanisms that characterize patients with HFpEF. Two possible targets include hemodynamic overload evidenced by increased LV diastolic pressure (LVDP) and myocardial fibrosis evidenced by increased extracellular matrix fibrillar collagen. The measurement of LVDP and fibrosis generally requires either invasive procedures and/or complex and sophisticated imaging techniques. However, biomarkers measured in the plasma have been shown to accurately reflect changes in hemodynamic load and myocardial fibrosis and may have important application to the management of patients with HFpEF. The purpose of this review is to describe current and future applications of biomarkers in the management of patients with HFpEF.
Indexed as
Identifiers
23716130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.